Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset.
European Neuropsychopharmacology. 2018-01-01; 28(1): 24-36
DOI: 10.1016/j.euroneuro.2017.11.020
Lire sur PubMed
1. Eur Neuropsychopharmacol. 2018 Jan;28(1):24-36. doi:
10.1016/j.euroneuro.2017.11.020.
Factors associated with direct health care costs in schizophrenia: Results from
the FACE-SZ French dataset.
Laidi C(1), Prigent A(2), Plas A(2), Leboyer M(1), Fond G(3), Chevreul K(4);
FACE-SCZ Group.
Collaborators: Aouizerate B(5), Andre M(6), Berna F(7), Capdevielle D(6),
Chereau-Boudet I(7), Dorey JM(8), Dubertret C(9), Dubreucq J(10), Faget C(11),
Lancon C(11), Leigner S(7), Llorca PM(7), Mallet J(9), Misdrahi D(5), Rey R(8),
Roux P(12), Schurhoff F(1), Urbach M(12), Vidailhet P(7).
Author information:
(1)Inserm, U955, Institut Mondor de la Recherche Biomédicale, Psychiatrie
Translationnelle, Créteil, France; Fondation Fondamental, Créteil, France; Pôle
de Psychiatrie, AP-HP, Faculté de Médecine de Créteil, DHU PePsy, Hôpitaux
Universitaires Henri Mondor, France; AP-HP, URC Eco Ile-de-France, Paris
F-75004, France.
(2)AP-HP, URC Eco Ile-de-France, Paris F-75004, France; University Paris
Diderot, Sorbonne Paris Cité, ECEVE, UMRS 1123, Paris F-75010, France.
(3)Fondation Fondamental, Créteil, France.
(4)AP-HP, URC Eco Ile-de-France, Paris F-75004, France; University Paris
Diderot, Sorbonne Paris Cité, ECEVE, UMRS 1123, Paris F-75010, France; Inserm,
ECEVE, U1123, Paris, F-75010, France. AP-HP, Robert-Debré University Hospital,
Department of Public Health, Paris F-75019, France. Electronic address:
.
(5)Centre Hospitalier Charles Perrens, Université de Bordeaux, F-33076 Bordeaux,
France.
(6)Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU
Montpellier, Université Montpellier, France.
(7)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg,
France; CMP B, CHU, EA 7280 Faculté de Médecine, Université d’Auvergne, BP 69
63003, Clermont-Ferrand Cedex 1, France.
(8)Université Claude Bernard Lyon 1/Centre Hospitalier Le Vinatier Pole Est BP
300 39, 95 bd Pinel, 69678 BRON Cedex, France.
(9)AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, Inserm
U894, Université Paris Diderot, Sorbonne Paris Cité, Faculté de médecine,
France.
(10)Centre Référent de Réhabilitation Psychosociale, CH Alpes Isère, Grenoble,
France.
(11)Pôle psychiatrie universitaire, CHU Sainte-Marguerite, F-13274 Marseille
cedex 09, France.
(12)Service de psychiatrie d’adulte, Centre Hospitalier de Versailles, UFR des
Sciences de la Santé Simone Veil, Université Versailles Saint-Quentin en
Yvelines, Versailles, France.
INTRODUCTION: There is a lack of data on health care consumption of patients
suffering from schizophrenia, as well as on the related health care costs.
Factors associated with health care costs have not been widely studied, whereas
knowledge on this topic would allow identifying risk factors and delineating
strategies to improve patients’ health and follow-up, likely to also decrease
health care costs. The aim of this study was to estimate the average direct
health care cost of patients with schizophrenia in France and to identify the
factors associated with this cost.
METHODS: The study population included patients with schizophrenia enrolled in
the FondaMental Advanced Centers of Expertise for Schizophrenia cohort. We
accounted for the costs directly related to the treatment of schizophrenia. They
included the costs of hospitalizations (full- and part-time), psychiatric
ambulatory consultations and medications. We studied three categories of factors
potentially associated with direct health care costs: demographic, socioeconomic
and clinical characteristics.
RESULTS: Three hundred and ninety five patients with schizophrenia were
included. The mean (median) annual direct health care cost per patient amounted
to €14,995 (€3,435). A lower level of functioning and being single were
associated with a higher cost. A significant association between the expert
center of inclusion and the direct health care cost of schizophrenia was also
highlighted.
CONCLUSION: Our results highlighted the significant cost of schizophrenia and
suggest that improvement in patient care, based on well-validated targeted
therapeutic interventions such as psycho-education and cognitive rehabilitation,
could reduce worsening in symptom severity and therefore decrease health care
costs.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.
DOI: 10.1016/j.euroneuro.2017.11.020
PMID: 29301707 [Indexed for MEDLINE]